Skip to content

9 Minutes for Tandem Colonoscopy Withdrawal

Impact of 9-minute Withdrawal Time on Adenoma Miss Rate: A Multicenter, Prospective, Randomized Controlled Trial of Tandem Colonoscopy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04797065
Enrollment
733
Registered
2021-03-15
Start date
2021-03-01
Completion date
2021-12-05
Last updated
2022-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon Polyp, Colorectal Adenoma

Keywords

withdrawal time, adenoma miss rate, tandem colonoscopy, adenoma detection rate

Brief summary

A mean withdrawal time of at least 6 minutes has been considered to be one of the critical quality criterions of colonoscopy. Recently, our group completed a multicenter randomized controlled trial, which proved that prolonging the withdrawal time to 9 minutes could significantly improve the adenoma detection rate of colonoscopists, especially for young colonoscopists and proximal colon. However, it has some limitations in included participates (mixed indications for colonoscopy) and cannot illustrate the impact of withdrawal time on adenoma miss rate in a parallel randomized design. It is necessary to include tandem colonoscopy and adopt strict criteria of the screening population to confirm the effect of the 9-minute withdrawal time on the adenoma miss rate. Therefore, the investigators plan to conduct a multicenter, randomized controlled trial of tandem colonoscopy to compare adenoma miss rate of 6-minute and 9-minute withdrawal in screening population.

Interventions

PROCEDURE6-minute then 9-minute withdrawal

Patients in 6-minute then 9-minute withdrawal group will first be carefully observed in 2 minutes then in 3 minutes during each colonic segment. In actual performance, withdrawal of the right colon, transverse colon and the left colon can be operated in segmental tandem colonoscopy. Taking the right colon as an example, after the endoscope reaches the cecum, it can be withdrawn to the splenic curvature in 2 minutes, then reentered the cecum and withdrawn to the splenic curvature in 3 minutes.

PROCEDURE9-minute then 6-minute withdrawal

Patients in 9-minute then 6-minute withdrawal group will first be carefully observed in 3 minutes then in 2 minutes during each colonic segment. In actual performance, withdrawal of the right colon, transverse colon and the left colon can be operated in segmental tandem colonoscopy. Taking the right colon as an example, after the endoscope reaches the cecum, it can be withdrawn to the splenic curvature in 3 minutes, then reentered the cecum and withdrawn to the splenic curvature in 2 minutes.

Sponsors

No.85 Hospital, Changning, Shanghai, China
CollaboratorOTHER
Yantaishan Hospital of Yantai City, Yantai, China
CollaboratorUNKNOWN
Seventh Medical Center of PLA Army General Hospital
CollaboratorOTHER
The First Affiliated Hospital of Dalian Medical University
CollaboratorOTHER
The First Affiliated Hospital of the Medical College, Shihezi University
CollaboratorUNKNOWN
Shanghai 8th People's Hospital
CollaboratorOTHER
Shanxi Provincial People's Hospital
CollaboratorOTHER_GOV
Qinghai People's Hospital
CollaboratorOTHER
Leqing People's Hospital
CollaboratorUNKNOWN
Affiliated Hospital of North Sichuan Medical College
CollaboratorOTHER
Zhejiang University
CollaboratorOTHER
Songjiang Hospital Affiliated to Shanghai Jiaotong University School of Medicine
CollaboratorOTHER_GOV
The General Hospital of Eastern Theater Command
CollaboratorOTHER
Heilongjiang provincial hospital
CollaboratorUNKNOWN
The Second Hospital of Hebei Medical University
CollaboratorOTHER
Changhai Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Patients whose age is between 40-75. * Patients who have indications for screening * Patients who have signed inform consent form.

Exclusion criteria

* Patients who have undergone colonic resection or polypectomy * Patients with alarming signs and symptoms of colorectal cancer: hematochezia, melena, anemia, weight loss, abdominal mass, positive digital rectal examination * Patients with abnormal blood coagulation or taking antiplatelets or anticoagulants within 7 days * Patients with inflammatory bowel diseases * Patients with a history of abdominal surgery, or highly suspected or confirmed colorectal cancers by radiographic and laboratory tests * Patients with hereditary colorectal cancer syndrome (including familial adenomatous polyposis). * Patients with pregnancy, severe chronic cardiopulmonary and renal disease. * Patients with failed cecal intubation * Patients with poor BPQ that necessitated a second bowel preparation * Patients with therapeutic colonoscopy for existing lesions * Patients refusing to participate or to provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
adenoma miss rate(AMR)60 minutesAdenomas detected in the second-pass examination were defined as missed adenomas; the AMR was defined as follows: number of adenomas detected in the second-pass examination/total number of adenomas detected in the two pass.

Secondary

MeasureTime frameDescription
advanced adenoma miss rate(AAMR)60 minutesAAMR is the number of advanced adenomas detected in the second-pass examination/total number of advanced adenomas detected in the two pass.
adenoma detection rate(ADR)60 minutesADR is the number of patients with at least one adenoma, divided by the total number of patients.
adenomas per colonoscopy(APC)60 minutesAPC was calculated as the number of adenomas detected during colonoscopy withdraw divided by the number of colonoscopies.
patient-level AMR(pAMR)60 minutesthe number of participants with adenomas detected only during the second-pass colonoscopy divided by the total number of participants with adenomas detected during the tandem colonoscopy

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026